Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...
Francis Medical is heating up with a 510(k) clearance from the FDA for its water vapor ablation therapy aimed at cancers of the prostate, kidneys and bladder. The regulatory go-ahead for its Vanquish ...
MINNEAPOLIS, Dec. 2, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of ...
MINNEAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of ...
An 82-year-old retired professor from the Indian Institute of Science, who spent a lifetime shaping young minds, suffered from urinary difficulties due to a severely enlarged prostate—also known as ...
Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA). Vanquish is a transurethral, ultrasound and ...
MINNEAPOLIS, July 19, 2023 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of ...
LAS VEGAS — Since its approval by the US Food and Drug Administration in 2015, transurethral water-vapor therapy has been gaining traction as an in-office procedure for reducing the symptoms of benign ...